Clinical Trials Browser

Unknown × INDUSTRY × Neoplasms, Plasma Cell × Clear all

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Neoplasm, Residual, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT03999697 2019-06-27

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Phase 1 Unknown

10 enrolled

LymphoidPlasma cell

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

98 enrolled

Plasma cell

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT01435720 2014-09-11

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Phase 1/2 Unknown

15 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Leukemia, Plasma Cell, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT01695590 2013-06-04

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma

Phase 1/2 Unknown

40 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Clinical Trials

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)

Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma